People who understand where medicines come from are sounding the alarm. In the largest grassroots effort in the history of the drug industry, we — alongside hundreds of biotech entrepreneurs, academic luminaries, patient advocates, and prominent investors — sent a letter to Congress explaining the drastic consequences of redefining the word “negotiation.” Others continue to add their names. The signers collectively represent nearly $187 billion in science-focused capital, 21,000 Americans employed in life sciences, and hundreds of drug candidates in clinical trials. We are motivated by a concern that Congress is about to extinguish the fight against disease and suffering that our community has dedicated itself to for decades.
Read more: Congress is about to legislate a future without new medicines. We have a better plan
